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Favorably Tipping the Balance
between Cytopathic and Regulatory T Cells
to Create Transplantation Tolerance
apoptotic pathways is required for the induction of pe-
ripheral transplant tolerance across MHC barriers with
treatments that do not directly kill T cells (Li et al., 1999;
Wells et al., 1999). Activated CD4CD25 T cells, which
are critical for transplantation tolerance (Graca et al.,
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Beth Israel Deaconess Medical Center 2002; Kingsley et al., 2002; Sanchez-Fueyo et al., 2002),
appear to be resistant to apoptosis (Banz et al., 2002;Harvard Medical School
2 Department of Medicine Papiernik et al., 1997). We hypothesized that a regimen
that includes agonist (wild-type) IL-2/Fc fusion proteinLaboratory of Immunogenetics and Transplantation
Brigham and Women’s Hospital (Zheng et al., 1999) as a component to enhance AICD, a
high-affinity IL-15R antagonist mutant IL-15/Fc fusionHarvard Medical School
Boston, Massachusetts 02215 protein (mIL-15/Fc) (Ferrari-Lacraz et al., 2001; Kim et
al., 1998) to block proliferative and antiapoptotic IL-
15 signals (Li et al., 2001; Waldmann et al., 2001), and
rapamycin (RPM) to block the early expansion of allore-Summary
active T cells without inhibiting signals 1 and 2 may
constitute a novel and potent tolerance-inducing proto-Therapeutic application of broadly reactive anti-T cell
col even in extremely stringent models by maximizingantibodies can lead not only to potent immunosup-
the selective depletion of donor-reactive cytopathic-pression but also to profound and long-lived T cell
type T cells while sparing or even enhancing the immu-depletion. We reasoned that a strategy that almost
nosuppressive effects of regulatory T cells. Recall thatexclusively targets activated cytopathic donor reac-
IL-2, a molecule that promotes apoptosis of proliferatingtive T cells and spares immunoregulatory networks
effector T cells (Lenardo, 1991; Van Parijs et al., 1999),might prove to be an exceptionally potent and highly
appears to be a survival factor for CD4CD25 regula-selective means of producing long-term engraftment
tory T cells (Banz et al., 2002; Malek et al., 2002; Pa-and tolerance. Herein we show that the combined ad-
piernik et al., 1998).ministration of rapamycin and agonist IL-2- and antag-
Our recent studies (Li et al., 1999; Wells et al., 1999)onist IL-15-related cytolytic fusion proteins provides
have emphasized the importance of maintaining the in-for long-term engraftment/tolerance in exceptionally
tegrity of apoptotic pathways in activated T cells tostringent allotransplant models by (1) limiting the early
achieve tolerance with therapies that foster immune de-expansion of activated T cells, (2) preserving and even
viation and anergy. We now report a strategy whichexaggerating their subsequent apoptotic clearance,
avoids blockade of both signals 1 and 2 and is specifi-and (3) further amplifying the depletion of these acti-
cally directed toward selective deletion of activatedvated T cells by antibody-dependent mechanisms,
cytopathic T cells by apoptosis and antibody (Fc)while (4) preserving CD4CD25 T cell-dependent im-
-dependent pathways. The agonist IL-2- and antagonistmunoregulatory networks.
IL-15-related proteins were designed as IgG2a-derived
Fc fusion proteins to ensure a prolonged circulating half-Introduction
life and also provide a potential means to kill activated
IL-2R and IL-15R target cells via the activation ofAllograft outcome, rejection or tolerance, often depends
complement and FcR leukocytes. Hence, the IgG2a-on the balance between cytopathic and regulatory
based complement-dependent (CDC) and antibody-T cells (Cobbold and Waldmann, 1998; Graca et al.,
dependent (ADCC) cell cytotoxicity-activating (Fc/) fu-2002; Kingsley et al., 2002; Sanchez-Fueyo et al., 2002).
sion proteins are potentially cytolytic proteins (Kim etDue to the large numbers of alloreactive T cells re-
al., 1998; Zheng et al., 1999). For comparison, we mu-sponding against allogeneic MHC molecules (Lindahl
tated the FcR binding and C1q binding domains of theand Wilson, 1977a, 1977b; Suchin et al., 2001; Teh et
Fc fragment (Fc/) to render these proteins incapableal., 1977), the induction of peripheral tolerance requires
of directing either CDC or ADCC (Kim et al., 1998; Zhengtrimming of the pool size of alloreactive T cells in order
et al., 1999), so that we might contrast the therapeuticto allow regulatory T cells to exert their suppressive
effects of lytic wild-type Ig fusion proteins (Fc/) andeffects (Li et al., 1999, 2001; Wells et al., 1999; Sanchez-
nonlytic mutant Ig proteins (Fc/). The regimen includesFueyo et al., 2002).
RPM to antagonize the proliferative response of acti-Activation-induced cell death (AICD) and passive cell
vated T cells to T cell growth factors (TCGF) withoutdeath (PCD) are routine downstream consequences of
inhibiting the AICD signal imparted by IL-2 (Bierer et al.,T cell activation by antigen (signal 1) plus costimulation
1990; Wells et al., 1999). Indeed, RPM blocks the TCGF-(signal 2) (Marrack et al., 2000), and the integrity of these
triggered expression of bcl-2 and bcl-XL (Adachi et al.,
1996; Boise et al., 1995), an action that potentially ampli-*Correspondence: tstrom@bidmc.harvard.edu (T.B.S.), xzheng@
fies the magnitude of apoptotic depletion of activatedbidmc.harvard.edu (X.X.Z.)
3These authors contributed equally to this work. T cells during the allograft response.
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Figure 1. Combined IL-2/Fc, mIL-15/Fc, and RPM Treatment Inhibits Alloantigen-Triggered CD4 and CD8 T Cell Proliferation In Vivo, and
Hastens the Expression of High-Affinity IL-2 Receptors and the Advent of Apoptosis among Activated T Cells
(A) Three days after adoptive transfer of CFSE-labeled NOD mononuclear leukocytes, 2-fold less total cells were recovered from the lymph
nodes and spleen of RPM-treated DBA/2 recipients as compared to control hosts (columns 1 and 2), and this reduction in the recovered
number was increased when RPM was coadministered with either nonlytic (column 3) or lytic (column 4) IL-2/Fc and mIL-15/Fc fusion proteins.
These results are representative of four independent experiments. (*  p  0.05; Mann-Whitney U test).
(B) Combined nonlytic IL-2/Fc/ and mIL15/Fc/ administration synergizes with RPM therapy to restrain both the frequency of allogeneic
CD4 and CD8 T cells entering cell cycle (divisions 1–8) and the magnitude of their subsequent proliferation. As compared to untreated
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Results and Discussion (26% reduction; p  0.02, Wilcoxon matched-pairs
signed-rank test) of CD4 and 12% (48% reduction; p
0.03) of CD8 CFSE-labeled T cells recovered from theCombined IL-2/Fc, mIL-15/Fc, and RPM Treatment
Inhibits Alloantigen-Triggered T Cell Proliferation spleens of hosts receiving combined treatment prolifer-
ated within this time period (data not shown; see FigureIn Vivo While Preserving the Subsequent
Apoptotic Clearance of Activated T Cells 1B for the results of a prototypic experiment with the
corresponding RF values). In addition, this regimen alsoT cell apoptosis and proliferation are typically linked,
as virtually all apoptotic events occur after a discrete restrained the proliferative capacity or number of waves
of replication conducted by the proliferating CD4 andnumber of T cell divisions (Li et al., 2001; Renno et al.,
1999). To test whether IL-2/Fc, mIL-15/Fc, and RPM CD8 T cells. Thus, in contrast to untreated controls, in
treated hosts CD4 and CD8 T cell proliferation wasadministration is capable of curtailing the proliferation
of alloactivated T cells without compromising their apo- not noted beyond the sixth wave of replication (see
Figure 1B for a representative experiment). It is notableptotic depletion, we first studied the effects of these
reagents in an in vivo graft-versus-host disease (GVHD)- that this treatment curtails the expansion and/or survival
of both CD4 and CD8 T cells, though the impact islike model in which CFSE-labeled NOD (H-2g7) lympho-
cytes were transferred into irradiated DBA/2 (H-2d) more profound on the CD8 subset. In this 3 day GVHD-
like model very little homeostatic proliferation occurs inhosts. On day 3 posttransfer, 50% less T cells were
recovered from RPM-treated as compared to control the absence of alloageneic stimulation, since only 5%
and 8% of CD4 and CD8 T cells, respectively, prolifer-hosts (Figure 1A, columns 1 and 2). Even fewer cells
were recovered when RPM was used in combination ate when adoptively transferred into syngeneic irradi-
ated recipients (data not shown). In addition, the thera-with IL-2/Fc and mIL-15/Fc fusion proteins (Figure 1A,
columns 3 and 4), indicating that combined treatment peutic effect upon T cell proliferation is identical in
GVHD-like models in which (1) the recipient is irradiatedhad a marked impact on the expansion and/or survival
of allogeneic T cells. The reduction in recovered T cells and lymphopenic, and (2) in a semiallogeneic parent-
into-F1 adoptive transfer model in which no lymphope-was greatest in the regimen utilizing lytic as compared
to nonlytic fusion proteins (Figure 1A, column 4). In the nia is induced (CD45.1 C57BL/6 into B6AF1; Figure 1E).
Thus, the antiproliferative effects of treatment in theabsence of RPM administration, the lytic fusion proteins
(IL-2/Fc/ or mIL-15/Fc/ monotherapy) were also CFSE-monitored GVHD-like model are not due to inhibi-
tion of homeostatic proliferation.more effective than their nonlytic counterparts in de-
creasing the number of alloantigen-activated IL-2R
or IL-15R T cells, respectively (data not shown). Combined IL-2/Fc, mIL-15/Fc, and RPM Treatment
Hastens the Expression of High-Affinity IL-2The effect of treatment on T cell proliferation was
analyzed in five independent experiments by determin- Receptors among Activated T Cells
The differential expression of IL-2R subunits upon acti-ing the responding frequency (RF) or frequency of alloge-
neic CFSE-labeled T cells that underwent cell division vated T cells has been linked to T cell survival and
apoptosis (Dai et al., 1999; Li et al., 2001). We hypothe-and were recovered from immunodeficient irradiated
hosts 3 days after cell transfer. While RPM monotherapy sized that the additive effect observed when combining
RPM plus IL-2/Fc and mIL-15/Fc fusion proteins mightsignificantly dampened the proliferation of CD4 and
particularly CD8 T cells, this inhibitory effect increased be due, in part, to an altered pattern of IL-2 receptor
protein expression upon activated T cells. In untreatedmarkedly when either the lytic or nonlytic fusion proteins
were coadministered with RPM. Thus, among the surviv- hosts, the IL-2R and IL-2R chains were rarely de-
tected during the first five cell divisions in recovereding CFSE-labeled T cells recovered from untreated con-
trol host spleens, the mean responding frequency in the CFSE-positive CD4 T cells, but markedly amplified ex-
pression of these receptor proteins was detected by thefive analyzed experiments was 19% for CD4 and 23%
for CD8 T cells (data not shown). In contrast, only 14% sixth cell division (Figure 1C). In parallel, a high fre-
hosts, in mice receiving combined therapy, CD4 and CD8 T cell proliferation is not noted beyond the sixth wave of replication (see vertical
dotted line). These effects are particularly profound in the CD8 T cell subset. Similar results were obtained when lytic IL-2/Fc/ and mIL-
15/Fc/ fusion proteins were administered in combination with RPM. Data from splenic CFSE-labeled T cells are shown here (similar results
were observed when analyzing lymph node cells). RF  frequency of allogeneic responding T cells that divided following cell transfer into
immunodeficient irradiated hosts.
(C) As compared to untreated controls, CD4 allogeneic T cells harvested from treated hosts manifest early expression of IL-2R and  chains
and earlier apoptosis (annexin V staining). Data obtained from a flow cytometric analysis of splenic CFSE-labeled CD4 T cells are displayed.
Although very few CD8 T cells proliferated in treated hosts, the pattern of staining for annexin V and IL-2R and  chains among proliferating
CD4 and CD8 T cells is similar. The data shown here were obtained from one experiment representative of five (the mean RF for the five
independent experiments is provided in the main text).
(D) Adoptively transferred CFSE-labeled CD4 T cells sorted at the second and third cell divisions from treated, but not untreated, irradiated
allogeneic hosts proliferate vigorously in vitro in the presence of exogenous rIL-2 (200 U/ml). The second and third division CD4 T cells
harvested from both treated and untreated mice proliferated vigorously when cultured in the presence of plate-bound anti-CD3 mAb. This
figure is representative of three independent experiments.
(E) Combined lytic IL-2/Fc/, mIL-15/Fc/, and RPM also inhibits CD4 and CD8 T cell proliferation in a nonlymphopenic GVHD-like model
in which CFSE-labeled CD45.1 C57BL/6 leukocytes are adoptively transferred into unmanipulated B6AF1 (CD45.2) recipients. Histograms
were obtained after gating on CD45.1/CD4- or CD45.1/CD8-positive cells (open histograms, untreated controls; closed histograms, treated
recipients). This is representative of three independent experiments.
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quency of annexin V-positive CD4 T cells was not ob- day 10. As expected from our previous CFSE experi-
served until the sixth cell division (Figure 1C). In contrast, ments, combined lytic IL-2/Fc/, mIL-15/Fc/, and
in CFSE-positive CD4 T cells recovered from RPM- RPM treatment almost completely blocked SEB-trig-
treated hosts, IL-2R and  chains, as well as annexin gered T cell proliferation (80%) without blunting the
V staining, were readily detected by the second cell subsequent disappearance of activated T cells (Figure
division, and the expression steadily increased with suc- 2A). It is notable that combined therapy did not compro-
cessive divisions (Figure 1C; similar results obtained for mise the survival of nonactivated V6 T cells (Figure
the CD8 T cell subset are not shown). The IL-2R chain 2B), proving the high selectivity of this regimen for acti-
was constitutively expressed on all dividing cells (data vated T cells.
not shown). These effects were magnified when either
lytic or nonlytic IL-2/Fc and mIL-15/Fc were adminis-
tered together with RPM (Figure 1C). It should be noted CD4CD25 T Cells Are Resistant to the Lytic Effects
that the administration of monotherapy with lytic or non- of IL-2/Fc
lytic IL-2/Fc fusion proteins, in contrast to the use of Insofar as many regulatory T cells active in transplanta-
combined treatment, enhanced T cell proliferation and tion tolerance bear the CD4CD25 phenotype (Hall et
did not increase the expression of annexin V and IL-2 al., 1990; Hara et al., 2001; Sanchez-Fueyo et al., 2002;
receptor  and  chains among proliferating T cells (data Taylor et al., 2001; Zelenika et al., 2002), we were con-
not shown). In short, these data indicate that RPM or cerned that the inclusion of a potentially cytolytic IL-2/
combined IL-2/Fc, mIL-15/Fc, and RPM administration Fc/ protein in our protocol might destroy the immuno-
expedites the early expression of high-affinity IL-2 re- regulatory networks responsible for peripheral toler-
ceptors. These results further suggest that the acquisi- ance. To address this issue, we compared the effects
tion of responsiveness to IL-2 at early cell divisions in of lytic IL-2/Fc/ with those of a depleting anti-CD25
the treated hosts could contribute to the early advent mAb (PC61) upon the viability of CD4CD25 T cells in
of apoptosis among activated T cells. To test the hypoth- naive mice. While a 1-week course of anti-CD25 mAb
esis that IL-2 responsiveness is actually acquired at treatment virtually eliminated all CD4CD25 T cells
early cell divisions in the treated hosts, we sorted CD4 present in secondary lymphoid tissue, the use of lytic
T cells at the second and third divisions from treated IL-2/Fc/ had no detectable impact on the number of
and untreated hosts and cultured them in the presence
CD4 T cells expressing CD25 in naive hosts (Figure 3A).
of rIL-2. Recall that only in treated hosts do proliferating
As CD4CD25 effector T cells express CD25 following
T cells undergo apoptosis at such early cell divisions
activation, the impact of IL-2/Fc/ on the survival of both
(Figure 1C). Anti-CD3 but not exogenous rIL-2 triggered
alloantigen-activated CD4CD25 and CD4CD25proliferation of CD4 T cells harvested from untreated
T cells was compared in a fully allogeneic adoptiveallogeneic mice (Figure 1D). In contrast, CD4 T cells
transfer model (Figure 3B). Purified CD45.1-positiveharvested from treated mice proliferated vigorously in
CD4CD25 and CD4CD25 T cells from naive C57BL/6the presence of rIL-2 (Figure 1D). We conclude, there-
mice were separately transferred into irradiated DBA/2fore, that the occurrence of early apoptosis is correlated
hosts. While lytic IL-2/Fc/ markedly reduced the num-with the early acquisition of IL-2 responsiveness. IL-2-
ber of CD4T cells recovered from the spleen of allogeneictriggered AICD, however, is not the sole mechanism
hosts adoptively transferred with CD4CD25 T cells, thisresponsible for early apoptosis in this system. IL-15R
treatment had a minor effect on the survival ofblockade and RPM not only prevent T cell expansion
CD4CD25 T cells (Figure 3B). We have observed abut also contribute to the overall T cell apoptotic effect.
consistent result in a more clinically relevant model, inThus, the low recovery of allogeneic lymphocytes in
which we compared the gene expression profile ofRPM plus nonlytic IL-2/Fc/ and mIL-15/Fc/ treated
T cells harvested from draining lymph nodes of treatedhosts (Figure 1A) can be attributed to the inhibition of
and untreated skin allograft recipients. While combinedT cell proliferation and to the occurrence of early T cell
IL-2/Fc/, mIL-15/Fc/, and RPM treatment markedlyapoptotic depletion by both AICD and PCD. In addition,
decreased the transcript level of granzyme B (Figureby the use of lytic IgG2a Fc tails attached to IL-2 and
3C), a well-established marker of allograft rejection (Lip-IL-15, this depletive effect is enhanced by antibody-
man et al., 1992, 1994), treatment had no significantdependent lytic mechanisms (Zheng et al., 1999).
effects on the relative expression of Foxp3 (Figure 3C), a
transcription factor exclusively expressed by regulatoryCombined IL-2/Fc, mIL-15/Fc, and RPM Treatment
T cells (Fontenot et al., 2003; Hori et al., 2003). TakenActs Exclusively upon Activated T Cells
together, these data indicate that the lytic effects of IL-To further test the hypothesis that the effects of com-
2/Fc/, mIL-15/Fc/, and RPM treatment are preferen-bined lytic IL-2/Fc/, mIL-15/Fc/, and RPM treatment
tially exerted upon alloantigen-activated, nonregulatory,are selective for activated T cells, we employed a super-
effector T cell populations. IL-2 is a viability factor forantigen-driven model in which Balb/c mice were chal-
regulatory T cells (Furtado et al., 2002; Malek et al., 2002;lenged with one dose of S. aureus enterotoxin B (SEB).
Papiernik et al., 1998; Walker et al., 2003). In fact, IL-2Three days following administration of SEB, a greater
triggers CD4CD25 T cells to express antiapoptoticthan 2-fold selective expansion of V8, but not V6,
genes (L. Turka, personal communication). Hence, weT cells was discerned in lymph nodes as compared to
hypothesize that the IL-2 component of IL-2/Fc/ fusionPBS-treated control mice (Figure 2A), and this expan-
protein may render these CD4CD25 T cells resistantsion was followed by a marked reduction in the cohort
of activated V8 T cells present in the lymph nodes by to antibody-triggered apoptotic cell death.
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Figure 2. Combined Lytic IL-2/Fc/, mIL-
15/Fc/, and RPM Administration Is Selec-
tive for Activated T Cells
Balb/c mice received a single i.p. injection
of SEB, and on days 3 and 10 the absolute
number of lymph node CD4V8,
CD8V8, CD4V6, and CD8V6
T cells was determined by flow cytometry.
Box plots representing total V8 (A) and
V6 (B) T cells are shown here (similar re-
sults were obtained for CD4 and CD8 T
subsets). n  5 for all three groups of mice.
(*  p  0.05; Mann-Whitney U test).
Combined IL-2/Fc, mIL-15/Fc, and RPM Treatment men, indicating that each of the components of the com-
bined regimen is required for optimal therapeutic effectsInduces Indefinite Engraftment of MHC-Mismatched
(Figure 5B). Finally, some skin allograft recipients wereSkin and Heart Allografts
treated with RPM plus costimulation blockade (CTLA4IgWe next studied the effects of our combined treatment
plus anti-CD154), since we had previously documentedregimen on the long-term survival of skin and heart allo-
that adjunctive RPM treatment provides synergistic ben-grafts in murine models in which monotherapy with RPM
efits to costimulation blockade-based regimens (Li etfails to induce long-term engraftment. Through the com-
al., 1999), but only a slightly prolonged engraftment ofbined use of nonlytic IL-2/Fc/ and mIL15/Fc/ plus
skin allografts was observed (Figure 5B).RPM, an apoptosis-promoting protocol, indefinite sur-
Transplantation of islet allografts into spontaneouslyvival of Balb/c (H-2d) skin grafted onto C3H/He (H-2k)
diabetic NOD hosts provides an even more dauntingrecipients (Figure 4A) and DBA/2 hearts transplanted
challenge than the skin allograft model because of theinto NOD mice (Figure 4B) was achieved in most cases.
generalized defect in tolerance mechanisms and theDespite this dramatic effect upon the allograft response,
presence of preactivated cytopathic islet-specific auto-universal acceptance of the skin and heart allografts
immune T cells (Maki et al., 1992; Noorchashm et al.,required the use of lytic IL-2/Fc/ and mIL-15/Fc/
2000). Indeed, using our islet isolation methods, as muchtogether with RPM apparently to maximize the clearance
as 60% of the islet allografts never function in this modelof activated T cells through both apoptotic and anti-
(Table 1) (Faust et al., 1996). Again, the combined regi-body-dependent mechanisms (Figures 4A and 4B).
men utilizing nonlytic fusion proteins failed to signifi-
cantly delay the rejection of allogeneic DBA/2 islets
Combined IL-2/Fc, mIL-15/Fc, and RPM Treatment transplanted into spontaneously diabetic NOD mice (Ta-
Promotes Very Long-Term Engraftment of Allogeneic ble 1). Interestingly, very long treatment (100 days) with
Islets in Spontaneously Diabetic NOD Mice RPM plus recombinant IL-2 has been recently shown
and IL-2-Deficient Recipients to enhance the apoptosis of autoreactive T cells and
NOD mice were purposely chosen as recipients due to prevent autoimmunity in NOD mice (Rabinovitch et al.,
their well-documented generalized resistance to tolerance 2002). In comparison to the regimens tested herein, the
induction (Markees et al., 1999). In order to further assess rIL-2 plus RPM protocol is most similar to the combina-
the ability of combined nonlytic IL-2/Fc/, mIL-15/Fc/, tion of RPM plus nonlytic IL-2/Fc/ (provision of the
and RPM treatment to promote long-term engraftment nonlytic tail to IL-2 creates a long-lived IL-2 with unim-
in some very stringent models, we then transplanted paired IL-2 bioactivity [Zheng et al., 1999]), a treatment
DBA/2 skin onto NOD mice. This combined protocol that proved ineffective in the NOD mouse allograft model
failed to significantly prolong the survival of DBA/2 skin (Figure 5B and Table 1). We cannot formally exclude
allografts (Figure 5A). In contrast, recipients treated with the possibility that prolonged treatment (100 days) with
lytic IL-2/Fc/, mIL-15/Fc/, and RPM exhibited mark- RPM plus nonlytic proteins would be effective.
edly prolonged engraftment (Figure 5B). Interestingly, We then examined the effects of combined lytic IL-2/
skin allograft rejection was only minimally to moderately Fc/, mIL-15/Fc/, and RPM treatment on the long-
delayed when recipients were treated with any single term survival of islet allografts in the NOD and IL-2
knocked-out (KO) models. IL-2KO mice display a lym-agent or two agent variation of the triple therapy regi-
Immunity
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Figure 3. Lytic IL-2/Fc/ or Combined Lytic IL-2/Fc/, mIL-15/Fc/, and RPM Treatment Preferentially Targets CD4CD25 T Cells
(A) Naive Balb/c mice received a 1-week course of either anti-CD25 mAb (three doses) or lytic IL-2/Fc/ (seven doses). While anti-CD25
treatment virtually eliminated all splenic CD4 T cells expressing CD25, lytic IL-2/Fc/ did not decrease the number of CD4CD25 T cells.
Similar results were observed in lymph node lymphocytes. The administration of nonlytic IL-2/Fc/ had no effect on the proportion of CD4
T cells expressing CD25 (data not shown). Data shown here are representative of four independent experiments.
(B) 106 CD45.1 C57BL/6 CD4CD25 or CD4CD25 T cells were adoptively transferred into irradiated IL-2/Fc/ treated or control DBA/2
(CD45.2) recipients The number of donor cells recovered from the spleen 3 days after transfer is shown here. This is one experiment
representative of four.
(C) The relative expression of the granzyme B and Foxp3 target genes was determined by real-time PCR on draining lymph nodes of control
or treated (RPM, IL-2/Fc/, and mIL-15/Fc/) skin allograft recipients 1 week after transplantation. In this method, we normalized expression
of the target genes to the housekeeping gene 18S, and data were expressed as relative fold difference between cDNA of the study samples
and a calibrated sample. Treatment resulted in marked decrease of granzyme B, but not Foxp3, gene expression. Results shown here are
mean  standard deviation of four independent experiments.
phoproliferative and autoimmune phenotype, presum- this setting (Dai et al., 1998; Wells et al., 1999). For
comparison, some recipients were treated with RPMably due to both the loss of IL-2-triggered AICD of anti-
gen-activated T cells (Kneitz et al., 1995) and the lack alone or RPM plus costimulation blockade (CTLA4Ig
plus anti-CD154). Combined lytic IL-2/Fc/, mIL-15/of effective regulatory T cells (Furtado et al., 2002; Malek
et al., 2002; Papiernik et al., 1998). Similar to NOD mice, Fc/, and RPM treatment, but not RPM or RPM plus
costimulation blockade, consistently promoted primaryIL-2KO mice exhibit a marked resistance to tolerance
induction, which leads to the failure of nonlymphoabla- graft function and very long-term survival of islet allo-
grafts in autoimmune diabetic NOD mice (Table 1) andtive therapies, which typically produce prolonged en-
graftment in wild-type hosts, to produce tolerance in indefinite allograft survival in IL-2KO C57BL/6 (H-2b) re-
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(Table 1). We have previously observed that, in order to
obtain primary graft function, a short period (1 week) of
pretreatment is mandatory (our unpublished data), most
likely due to the presence in diabetic NOD mice of preac-
tivated islet-destroying T cells. Hence, we believe that
our treatment strategy targets activated autoreactive as
well as alloreactive T cells.
CD4CD25 Regulatory T Cells Are Critical to Ensure
Indefinite Allograft Survival after Combined IL-2/Fc,
mIL-15/Fc, and RPM Treatment
In order to test whether combined RPM plus lytic IL-2/
Fc/ and mIL-15/Fc/ treatment could induce not only
indefinite engraftment but also alloantigen-specific im-
munological tolerance, we placed second same-donor
or third-party strain allografts into some recipients bear-
ing long-surviving allografts. NOD heart recipients 	60
days posttransplantation accepted second DBA/2 (n 
3;	80 days) but not third-party C57BL/6 heart allografts
(n  2). Similarly, among the six C3H/He recipients with
long-term engraftment of Balb/c skin allografts (Figure
5B), four accepted second Balb/c skin allografts (	60
days) while the remaining two promptly rejected third-
party C57BL/6 skin. These experiments were all per-
formed at least 30 days after treatment withdrawal. The
finding that the animals that carried long-term grafts
were able to accept grafts from the same donor but not
from third parties suggests that combined lytic IL-2/
Fc/, mIL-15/Fc/, and RPM treatment is capable of
inducing donor-specific tolerance. Moreover, when we
tested in an adoptive transfer system (Sanchez-Fueyo
et al., 2002) for the ability of T cells harvested from
tolerant NOD heart recipients to prevent the rejection
of same donor DBA/2 heart allografts mediated by naive
T cells, we found that T cells harvested from tolerant
hosts were indeed capable of mediating alloantigen-
specific immunosuppressive effects (Figure 6A). Consis-
tent with previous publications (Graca et al., 2002; Hara
et al., 2001; Kingsley et al., 2002; Sanchez-Fueyo et al.,
2002), the presence of CD4CD25 T cells among theFigure 4. Combined IL-2/Fc, mIL-15/Fc, and RPM Treatment Cre-
ates Tolerance to Skin and Heart Allografts in Various Murine Models tolerant lymphocytes was critical to ensure effective im-
(A) Combined nonlytic fusion proteins plus RPM treatment, but not munoregulation (Figure 6B). Although these experi-
RPM alone, leads to indefinite survival of most MHC-mismatched ments were performed using a limited number of recipi-
Balb/c skin allografts placed onto C3H/He recipients. Nonetheless, ents, our results suggest that peripheral immunological
only combined treatment with the lytic fusion proteins plus RPM led
tolerance to allogeneic tissues can be achieved in theto universal indefinite survival and tolerance of these skin allografts.
NOD model.Moreover, these recipients bearing long-time surviving skin allo-
To further address the role of CD4CD25 T cells ingrafts accept second same-donor strain allografts (n 4) but reject
third-party strain grafts (n  3). the induction of transplantation tolerance through com-
(B) Although combined nonlytic IL-2/Fc/, mIL-15/Fc/, and RPM bined lytic IL-2/Fc/, mIL-15/Fc/, and RPM treat-
treatment promotes indefinite acceptance of most DBA/2 heart allo- ment, we treated C3H/He mice with a short course of
grafts transplanted into NOD mice, only the regimen utilizing lytic
depleting anti-CD25 mAb (PC61), and then placed Balb/cIL-2/Fc/, mIL-15/Fc/ fusion proteins plus RPM ensures indefinite
skin allografts under the cover of our combined lyticsurvival of heart allografts in all cases. None of the recipients receiv-
protein regimen. CD25-depleted skin allograft recipientsing RPM alone achieve long-term graft survival. Long-time surviving
(	100 days) heart recipients treated with combined RPM plus either rapidly rejected their grafts once combined treatment
lytic or nonlytic IL-2/Fc and mIL-15/Fc fusion proteins accept sec- was discontinued (n 4; data not shown). Therefore our
ond same-donor strain allografts (n  3 and 3, respectively) but data strongly suggests that, in contrast to conventional
reject third-party strain tissues (n  2 and 2, respectively).
effector T cells, regulatory CD4CD25 T cells are resis-
tant to both the apoptotic and antibody-dependent cell
death-promoting effects mediated by combined IL-2/
Fc/, mIL-15/Fc/, and RPM treatment. This is consis-cipients (Figure 5C). In addition, combined treatment
with lytic fusion proteins plus RPM was the only regimen tent with recently published reports indicating that IL-2,
far from priming CD4CD25 T cells for apoptosis, actu-capable of achieving universal immediate graft function
of the transplanted allogeneic islets in the NOD model ally promotes their survival (Furtado et al., 2002; Malek
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et al., 2002; Walker et al., 2003). The importance of
CD4CD25 T cells in the conduct of transplantation
tolerance with combined lytic IL-2/Fc/ and mIL-15/
Fc/ plus RPM treatment was further emphasized by
the failure of IL-2KO islet recipients, known to be defi-
cient in CD4CD25 regulatory T cells (Furtado et al.,
2002; Malek et al., 2002; Papiernik et al., 1998), to accept
second same-donor islet allografts, even 	100 days
after successful engraftment (n  3; data not shown).
These data indicate that in the absence of effective
CD4CD25 T cell dependent immunoregulation, wide-
spread deletion of alloreactive T cells may lead to im-
mune ignorance, but not immunological tolerance.
In short, we have tested a therapeutic regimen that
utilizes nonlytic IL-2/Fc/ and mIL-15/Fc/ proteins
plus RPM to limit the early antigen-triggered expansion
of T cells and to amplify the subsequent selective apo-
ptotic clearance of activated T cells. This strategy has
proven highly successful in several allograft models, but
not in those that employ tolerance-resistant recipients.
In contrast, a regimen that includes lytic IL-2/Fc/and
mIL-15/Fc/ plus RPM is highly effective in several tol-
erance-resistant allo-transplant models. The lytic fusion
proteins were designed to augment the selective destruc-
tion of apoptosis-prone activated T cells via antibody-
dependent mechanisms. This protocol differs from many
other potent cell-deleting tolerance-producing regi-
mens in that broad lymphoablation is avoided and the
selective destruction of cytopathic T cells is achieved
without compromising the regulatory CD4CD25 T cell
subset. Through the use of this strategy we report that
NOD mice can be rendered tolerant to allogeneic tissues
and undergo long-term engraftment of islet allografts,
and that indefinite survival of MHC-mismatched alloge-
neic islets can be accomplished in the IL-2KO model.
Finally, our study has obvious conceptual relevance for
the design of new tolerizing protocols, since it suggests
that even the transient achievement of very extensive
lymphoablation may not suffice to ensure tolerance in
very stringent circumstances unless a provision is made
to preserve regulatory T cells.
Experimental Procedures
Animals
Eight- to twelve-week-old DBA/2 (H-2d), NOD/Lt (H-2g7), B6AF1
(H-2b/k.d), C57BL/6 (CD45.1 or CD45.2, H-2b), C57BL/6 homozygous
for a targeted disruption of the IL-2 gene (IL-2KO), Balb/c (H-2d),
C3H/He (H-2k), and B6AF1 (H-2b/k.d) mice were all obtained from
Jackson Laboratory (Bar Harbor, ME). The incidence of diabetes in
25-week-old female NOD/Lt was 75% (n  60).
Reagents and Treatment Protocols
Mouse CTLA4/Fc, cytolytic IL-2/Fc/, and mIL-15/Fc/, and non-
cytolytic IL-2/Fc/ and mIL-15/Fc/ fusion proteins were con-
structed and expressed in our laboratory as described (Kim et al.,Figure 5. Combined Lytic IL-2/Fc/, mIL-15/Fc/, and RPM Ad-
1998; Steurer et al., 1995; Zheng et al., 1999). B cell hybridomas wereministration, but Not Other Therapeutic Regimens, Enables Long-
purchased from American Type Culture Collection (ATCC, Rockville,Term Engraftment of Skin and Islet Allografts in Very Stringent NOD
and IL-2KO Models
(A) Combined nonlytic treatment fails to enable significantly pro-
longed survival of skin DBA/2 allografts placed onto NOD mice.
(B) Combined lytic IL-2/Fc/, mIL-15/Fc/, and RPM treatment, (C) Combined treatment with the triple agent regimen employing
but not the use of only two components of this regimen, enables lytic fusion proteins consistently ensures indefinite survival of DBA/2
long-term survival of 83% of DBA/2 skin allografts placed into NOD islets grafted into IL-2KO C57BL/6 recipients. None of the recipients
mice (monotherapy with any component also failed to show signifi- receiving RPM alone or RPM plus costimulation blockade achieved
cant prolongation of skin allograft survival; data not shown). long-term graft survival.
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Table 1. Combined IL-2/Fc, mIL-15/Fc, and Rapamycin Treatment Ensures Primary and Long-Term Function of Allogeneic Islets in
Spontaneously Diabetic NOD Mice
Primary Among Recipients
Treatment Functiona with Primary Function
MSTb n
No treatment 40% 6 7
RPM 50% 12 6
MR1  CTLA4Ig  RPM 75% 30 4
IL-2/Fc/  mIL-15/Fc/  RPM 100% 	110 8
IL-2/Fc/  mIL-15/Fc/  RPM 50% 16 4
a Defined as blood glucose 200 mg/dl 3 days after transplantation.
b Mean survival time.
MD), producing (1) a hamster mAb against mouse CD154 (MR1, days, and the remaining allograft recipients received 2 weeks of
treatment starting on the day of transplantation. RPM was given i.p.IgG2a, ATCC HB11048) and (2) a rat anti-mouse CD25 (PC61 5.3,
IgG1, ATCC TB222). RPM was provided by S. Sehgal (Wyeth-Ayerst, at a dose of 3 mg/kg or 1 mg/kg for heart recipients, daily for the
first 7 days, and every other day thereafter. IL-2/Fc/ and mIL-15/Princeton, NJ). Treatment of autoimmune diabetic NOD islet recipi-
ents was initiated 7 days prior to transplantation and administered Fc/ (as well as IL-2/Fc/ and mIL-15/Fc/) were administered
i.p. at a dose of 5 
g daily. MR1 and CTLA4/Fc were administeredfor 4 weeks. Skin allograft recipients were treated for a total of 28
Figure 6. Lymphocytes Harvested from Tol-
erant NOD Hosts Inhibit the Capacity of T
Cells from Naive NOD Mice to Reject Alloge-
neic Hearts, and This Effect Is Dependent on
the CD4CD25 T Cell Subset
(A) The transfer of 40 106 mononuclear leu-
kocytes from tolerant NOD heart recipients
into irradiated NOD hosts induces rapid rejec-
tion of third-party strain (C57BL/6), but not
donor strain (DBA/2), heart allografts. In con-
trast, irradiated NOD hosts receiving 10 
106 mononuclear leukocytes from naive NOD
hosts promptly reject DBA/2 heart allografts.
(B) The cotransfer of 40  106 mononuclear
leukocytes from tolerant hosts together with
10 106 from naive mice abrogates the ability
of mononuclear leukocytes from naive ani-
mals to rapidly reject allografts. The ability of
mononuclear leukocytes to block rejection in
this adoptive transfer model is lost if




i.p. at a dose of 0.25 and 0.2 mg, respectively, every other day for Adoptive Transfer Experiments
NOD mice were lethally irradiated with 800 rads (GammaCell irradia-four doses. In selected recipients three doses of 200 
g of CD25
mAb were administered every other day. We have previously deter- tor, Kanata, Canada) to effectively ablate their immune system, and
various mixtures of mononuclear leukocytes from naive and/or toler-mined that anti-CD25 mAb administered at such doses eliminates
more than 80% of CD4CD25 T cells in secondary lymphoid ant NOD hosts were injected through the tail vein. Mice were then
transplanted with DBA/2 or third-party strain (C57BL/6) heart allo-organs.
grafts. In selected experiments tolerant mononuclear leukocytes
were depleted of CD4CD25 T cells by the use of biotinylated anti-
SEB Treatment and Quantitation of SEB-Reactive Cells CD25 (7D4; Pharmingen) and anti-biotin magnetic beads (Miltenyi
Balb/c mice received one dose of 50 
g/mouse of SEB (Sigma, St. Biotech, Auburn, CA) according to the manufacturer’s instructions.
Louis, MO) in a single i.p. injection on day 0, and control mice were
injected with an identical volume of PBS. Mice received IL-2/Fc (5 Real-Time PCR Experiments

g i.p.), mIL-15/Fc (5 
g i.p.), and RPM (3 mg/kg) on days 0, 1, and Total RNA was extracted from draining lymph nodes with the
2 for the experimental group sacrificed on day 3, and daily on days RNeasy kit (Qiagen, Valencia, CA), and reverse transcription was
0 to 9 for the experimental group sacrificed on day 10. Single-cell performed using Multiscribed Reverse Transcriptase Enzyme (PE
suspensions were prepared from harvested axillary, inguinal, and Applied Biosystems, Foster City, CA). Real-time PCR was performed
mesenteric lymph nodes, subjected to hypotonic erythrocyte lysis, with the ABI 7700 sequence detector system (PE Applied Biosys-
and stained using PE-labeled mAb against CD4 (GK 1.5) or CD8 tems). To quantify the levels of mRNA, we normalized expression
(53-6.7), and FITC-labeled mAb against V6 (RR4-7) and V8 (F23.1; of the target genes to the housekeeping gene 18S, and data were
all obtained from Pharmingen, San Diego, CA). The frequencies of expressed as relative fold difference between cDNA of the study
these cell types was determined by flow cytometry on a FACSCaliber samples and a calibrated sample. Foxp3 primer/probe sequences
instrument (Becton Dickinson, Mountain View, CA), and the absolute are as follows: probe, 5-ATCCTACCCACTGCTGGCAAATGGAGTC-
number of lymph node CD4V8, CD8V8, CD4V6, and 3; forward primer, 5-CCCAGGAAAGACAGCAACCTT-3; reverse
CD8V6 T cells was determined by multiplying these percentages primer, 5-TTCTCACAACCAGGCCACTTG-3. 18S and granzyme B
by the total number of cells recovered from the harvested lymph primer/probe set were purchased from Applied Biosystems.
nodes.
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